clinical trial · NCT06390956
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Marginal Zone LymphomaPirtobrutinibRituximab
brief summary
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
started
Feb 20, 2025
primary completion
Dec 1, 2031
completion
Dec 1, 2032
last updated
Dec 4, 2025
official title
A Phase II Study of Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol